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Abstract
Leishmania mexicana can cause both localized (LCL) and diffuse (DCL) cutaneous leishmaniasis, yet little is known about
factors regulating disease severity in these patients. We analyzed if the disease was associated with single nucleotide
polymorphisms (SNPs) in IL-1b (2511), CXCL8 (2251) and/or the inhibitor IL-1RA (+2018) in 58 Mexican mestizo patients
with LCL, 6 with DCL and 123 control cases. Additionally, we analyzed the in vitro production of IL-1b by monocytes, the
expression of this cytokine in sera of these patients, as well as the tissue distribution of IL-1b and the number of parasites in
lesions of LCL and DCL patients. Our results show a significant difference in the distribution of IL-1b (2511 C/T) genotypes
between patients and controls (heterozygous OR), with respect to the reference group CC, which was estimated with a
value of 3.23, 95% CI=(1.2, 8.7) and p-value=0.0167), indicating that IL-1b (2511 C/T) represents a variable influencing the
risk to develop the disease in patients infected with Leishmania mexicana. Additionally, an increased in vitro production of
IL-1b by monocytes and an increased serum expression of the cytokine correlated with the severity of the disease, since it
was significantly higher in DCL patients heavily infected with Leishmania mexicana. The distribution of IL-1b in lesions also
varied according to the number of parasites harbored in the tissues: in heavily infected LCL patients and in all DCL patients,
the cytokine was scattered diffusely throughout the lesion. In contrast, in LCL patients with lower numbers of parasites in
the lesions, IL-1b was confined to the cells. These data suggest that IL-1b possibly is a key player determining the severity of
the disease in DCL patients. The analysis of polymorphisms in CXCL8 and IL-1RA showed no differences between patients
with different disease severities or between patients and controls.
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Introduction
Leishmania mexicana can cause a wide spectrum of clinical diseases,
ranging from a localized cutaneous ulcer at the infection site, which is
characteristic for patients with localized cutaneous leishmaniasis
(LCL), to a disseminating disease, where intensely parasitized
macrophages form nodules that spread throughout the skin and
ultimately invade the oropharyngeal and nasal mucosae, which is
characteristic for patients with diffuse cutaneous leishmaniasis (DCL).
Whereas LCL patients have a cellular immune response associated
with macrophage-activating cytokines such as IFN-c, DCL patients
lack an effective cellular immune response, permitting an uncon-
trolled replication of the parasites within macrophages and other
phagocytic cells. Little is known regarding the factors involved in
modulating the disease outcome; one of the possible factors are early
inflammatory mediators [1–5]. An excessive inflammatory response
can lead to increased neutrophil infiltration, which has been
associated with disease progression [6,7]. The observation that
enhanced neutrophil recruitment contributes to disease susceptibility
has been confirmed in experimental mouse models, which showed
that an improvement in disease outcome was associated with a
decrease in neutrophil immigration into the lesions [8]. One of factors
responsible for neutrophil infiltration is IL-1b [9]. This cytokine also
induces other innate mediators such as acute phase proteins and
chemokines such as IL-6 and CXCL8 (IL-8), respectively [10].
Production of active IL-1b by monocytes is promoted by
inflammasomes in response to diverse stimuli such as infections
[11,12]. NALP3, which belongs to the large family of intracellular
Nod-like receptors (NLRs), associates by oligomerization with
other intracellular proteins to form a complex known as the
inflammasome, which converts inactive procaspase 1 to active
caspase 1. This enzyme then cleaves the inactive IL-1b precursor
to a secreted active IL-1b [13].
Single nucleotide polymorphisms (SNPs) of IL-1b have been
associated with susceptibility towards various inflammatory
diseases, such as gastric cancer [14,15], periodontal disease [16],
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others. IL-8 (2251) has been associated with an increased risk to
develop H. pylori-associated gastroduodenal disease [19]. Vair-
aktaris et al. (2005) [20] suggested that IL-8 (2251) may be a
major contributor to genetic risk factor in oral cancer. IL-1RA
(+2018) has been shown to be associated with a significant increase
in the risk of developing fibrosing aveolitis [21].
Even though elevated levels of mRNA IL-1b have been
reported in biopsies of patients with American cutaneous
leishmaniasis [22], neither IL-1b (2511), CXCL8 (2251) nor
IL-1RA (+2018), have been associated with disease in leishman-
iasis. In this work we analyzed these SNPs in mononuclear cells of
patients with different clinical forms of cutaneous leishmaniasis.
Additionally, we analyzed the in vitro production of IL-1b by
patient monocytes, the expression of IL-1b in the sera and the
cytokine distribution in the cutaneous lesions of both groups of
patients. We found that polymorphism in IL-1b (2511 C/T) is
associated with a higher risk to contract the disease when the
patients are infected with Leishmania mexicana. We were also able to
demonstrate that patients with the more severe form of the disease
that harbor a larger number of Leishmania mexicana parasites, show
an enhanced in vitro production of IL-1b by monocytes, an
increased serum expression of IL-1b and a diffuse distribution of
IL-1b in the lesions.
The analysis of polymorphisms in CXCL8 and IL-1RA showed
no differences between patients and controls (data not shown).
Materials and Methods
Ethical statement
This study was conducted according to the principles expressed in
the Declaration of Helsinki. The study was approved by the
Institutional Ethics Committee of the Medical Faculty of the National
Autonomous University of Mexico (FMED/CI/RGG/013/01/
2008) and guidelines established by the Mexican Health Authorities
were strictly followed. All patients provided written informed consent
for the collection of samples and subsequent analysis.
Patients and controls
For the analysis of IL-1b polymorphism a total of 58 LCL
patients, 6 DCL patients and 123 control cases were included.
Patients were unrelated individuals and were clinically diagnosed
as LCL or DCL by Giemsa-stained smears of the lesions and
Montenegro skin hypersensitivity test taken at the sanitary
jurisdiction office of the Cunduaca ´n Municipality in Tabasco
State, located in southeastern Mexico. The diagnosis was
confirmed by an ELISA test for Leishmania in our laboratory.
The controls had no history of the disease and were negative in the
ELISA test for Leishmania. Both, patients and controls lived in La
Chontalpa - a region in the state of Tabasco, Mexico, with a
population of Maya ancestry mainly characterized as Mexican-
mestizo. This area is endemic for leishmaniasis and patients were
chosen based on the requirement that they had been locals for at
least three generations so the admixture analysis could be done
assuming the usual parental populations.
Genomic DNA extraction and typing assays
Blood samples were taken from patients and controls and
peripheral blood mononuclear cells (PBMC) were obtained by
density-gradient centrifugation with Ficoll-Hypaque (Sigma-Al-
drich St. Louis, MO, USA). Mononuclear cells were suspended in
1 mL of TRIZOL Reagent (Invitrogen Carlsbad, CA, USA),
mixed and incubated for 5 min at RT. Then, 0.2 mL chloroform
were added (Sigma). The resulting solution was mixed and
centrifuged at 193576g for 15 min at 4uC. The transparent phase
was discarded and 0.5 mL of absolute ethanol were added (Sigma).
The resulting solution was mixed and centrifuged at 193576g for
10 min at 4uC. The supernatant was discarded and 1 mL sodium
citrate 100 mM (Sigma) was added to wash the pellet, it was mixed
30 min at RT and centrifuged twice at 21516g for 5 min at 4uC.
The pellet was washed with 1 mL ethanol 75%, mixed during 20 s
and centrifuged at 21516g for 5 min at 4uC. The ethanol was
dried at RT and the pellet was suspended in RNase free water.
The presence of SNPs was analyzed for IL-1b 2511 (rs16944;
TaqMan C_1839943_10), IL-1RA +2018 (rs419598; TaqMan
C_8737990_10) and CXCL8 2251 (rs4073; TaqMan
C_11748116_10) using 20 ng genomic DNA for the PCR analysis.
Allelic discrimination was done using VIC and FAM fluorogenic
TaqMan probes and the 59 nuclease assay. The PCR conditions
included a step at 50uC for 2 min, a polymerase activation step at
95uC for 10 min followed by 40 cycles at 95uC during 15 s and
60uC for 1 min. These assays were done in a 7900 HT Fast Real
Time PCR System. The call rates we established for the analysis
were 90% individually (for every sample) and for every SNP.
Experimentally the call rate we found was 99% for IL-1b, 99.5%
for IL-1RA and 92% for CXCL8 (IL-8).
Statistical Analysis
For genotyping, the statistical analysis was done with Universal
R software.
For every SNP in the analysis, the genotype and allele
frequencies were calculated and contingency tables were pro-
duced. The Hardy Weinberg equilibrium was calculated only in
the control group using the Pearson Chi-squared test. The
genotype frequencies were compared among cases and controls.
The homozygote, heterozygote and serological ORs were calcu-
lated with both homozygote groups of reference. The statistical
significance of these was evaluated using a Chi-squared test for
association with a p-value of p#0.05 as the threshold. Since each
of these SNPs was selected for biological reasons before the data
was collected, multiple comparison issues were not considered
appropriate. Woolf [23] confidence intervals were also calculated.
Author Summary
Leishmania mexicana is an intracellular parasite that causes
two polarly opposed diseases: One is a self-limited disease,
characterized by ulcerative lesions associated with a low
infectious load, as found in patients with localized
cutaneous leishmaniasis (LCL). And the other pole is
characterized by a progressive disease where abundant
parasites spread uncontrollably throughout the skin inside
heavily infected phagocytic cells, as occurs in patients with
diffuse cutaneous leishmaniasis (DCL). The cause of this
severe form of the disease is unknown, although the early
encounter between the parasite and the inflammatory
response of the host possibly plays a decisive role in the
disease outcome. We here show that polymorphism in the
gene encoding IL-1b (2511 C/T) represents a variable
influencing the risk to develop the disease for patients
infected with Leishmania mexicana. In vitro experiments
showed that monocytes of DCL patients secreted signif-
icantly higher levels of the proinflammatory cytokine IL-1b
as compared to LCL patients. DCL patients also had
augmented levels of IL-1b in serum, and the cytokine was
diffusely distributed throughout lesions, which was corre-
lated with the numbers of parasites in the lesions. We
propose that IL-1b possibly plays a key role in establishing
the disease severity in patients infected with Leishmania
mexicana.
IL-1b in Patients Infected with L. mexicana
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polymorphism, the heterozygote group has a higher risk for disease
development than the two homozygote ones.
The statistical analysis of the data for parasite numbers,
Western-blot and ELISA tests, where different numbers of patients
and controls were included, was done using the Mann Whitney
test and p#0.05 was considered significant. These statistical
analyses were done using the Prism 5 software (GraphPad
Software, San Diego, CA, USA).
Analysis of serum IL-1b by Western-blot
The serum expression of IL-1b was analyzed by Western-blot in
9 LCL patients, 7 DCL patients and 4 controls. Venous blood was
drawn and allowed to clot at 37uC for 2 h. Serum was separated
by centrifugation at 5766g for 10 min at 4uC. Sera were diluted
1:2 with glycerol and stored at 220uC. For the Western-blot
analysis, protein concentration was determined using DC Protein
Assay Reagents Package (Bio-Rad Laboratories, Hercules, CA,
USA) and 120 mg of serum protein were analyzed by SDS–PAGE
in 15% acrylamide gels. Proteins were transferred onto Immobi-
lon-P membranes using a semidry electroblotting apparatus. The
membranes were blocked with 5% milk in Tris-buffer saline-
Tween 20 (TBST: 10 mM Tris–HCl, pH 7.4, 0.15 M NaCl, and
0.05% Tween 20) for 1 h at RT. Blots were incubated with
cleaved IL-1b (Asp116) polyclonal antibody (17 kDa, mature form
of human IL-1b) (2021S, Cell Signaling Technology, Danvers,
MA, USA) diluted in TBST with 5% BSA at 4uC overnight with
shaking. Anti-rabbit IgG, HRP-linked (Cell Signaling Technology)
diluted 1:3000 in 5% non-fat dry milk was used as secondary
antibody with shaking at RT for 1 h. Blots were developed using
Luminata Forte Western HRP substrate (Millipore Corporation,
Billerica, MA, USA) and exposed to X-ray films. The densito-
metric analysis was performed by recording the intensity of the
bands with a MultiImage Analyzer (Alpha Innotech Corporation)
based on the percentage of integrity density value (IDV).
Monocyte purification
For the analysis of the in-vitro production of IL-1b by monocytes
isolated from human PBMC, blood samples were taken from 5
patients with cutaneous leishmaniasis with varying degrees of
disease severity which included 3 LCL patients, one DCL patient
with a lesser degree of dissemination and one DCL patient who
was severely infected, having numerous nodules covering the
entire body surface. As for controls, blood samples from 7 healthy
individuals were used, of which 3 were born and lived within the
same geographical area as the LCL and DCL patients, but had
been never developed the disease. The other 4 blood samples were
obtained from healthy blood donors of the General Hospital of the
Ministry of Health in Mexico City. Cells were separated by
gradient centrifugation using Ficoll-Hypaque and mononuclear
cells were isolated from the interface and washed. For the
purification of monocytes, magnetically-labelled CD14 microbe-
ads (Miltenyi Biotec, Bergisch Gladbach, Germany) were used.
CD14+ monocytes were washed and plated in 24-well culture-
plates.
Cytokine measurement
The IL-1b production by non-stimulated monocytes was
analyzed as follows: 1610
6 cells were incubated for 18 h at
37uC and 5% CO2 in 1 mL RPMI-1640 (Gibco, Grand Island,
NY) medium, supplemented with 10% heat-inactivated FBS,
endotoxin free (Gibco). The cell-free supernatants from cultures
were harvested and the concentrations of the cytokine were
determined by ELISA. 96-well microtiter plates (Costar, Corning,
NY) were coated and sealed overnight at 4uC with assay diluent
and unconjugated anti-cytokine capture antibody (88–7010
eBioscience). The wells were washed 5 times with wash buffer,
blocked at RT for 1 h with assay diluent and washed again. The
standard curve was performed with 2-fold serial dilutions (from 3.9
to 500 pg/mL) and samples were incubated overnight at 4uC and
washed. Avidin-HRP diluted in assay diluent was added and
incubated at RT for 30 min and washed 7 times with wash buffer.
Each well was incubated for 15 min at RT with substrate solution
and the stop solution was added. The plate was read in a mQuant
spectrophotometer (BIO-TEK, Vermont, USA) at 450 nm using
the KC4 v3.4 program for the analysis of samples.
Immunohistochemistry (IHC) of tissue lesions
Skin punch biopsies (4–6 mm) were taken from the lesions of 6
DCL patients and 11 LCL patients; 8 of these LCL patients had 1
lesion ranging between 1 and 1.5 cm and 3 of the LCL patients
had multiple lesions [3 to 6] ranging between 1 and 2 cm. The
tissues were embedded in OCT compound and snap-frozen. They
were cut into 4-mm thick slices, fixed in acetone PA (J. T. Baker)
for 10 min at RT and hydrated in Tris-HCl 0.01M, NaCl 0.15M
pH=7.4. Samples were blocked for endogenous peroxidase
(Peroxo-Block, Invitrogen) and for nonspecific staining (protein
block solution, Abcam, Cambridge, UK). Thereafter, samples
were stained with anti-IL-1b (1:100, ab8320, Abcam) or mouse
anti-Leishmania mexicana immune sera for 1 h at RT and secondary
antibodies were used as specified by the manufacturer (mouse and
rabbit specific HRP/AEC detection IHC kit, ab94705, Abcam).
The slides were counterstained with Mayer’s haematoxylin
(Biogenex, CA, USA). Normal skin without lesions was used as a
negative-control. Digital images of tissue sections were captured
using a light microscope and a color AxioCam MRc5 camera
(Zeiss, Germany). In order to obtain the number of parasites in
lesions of LCL and DCL patients, 7 pictures of each tissue were
taken with a final area corresponding to 1 mm
2. Additionally, 6
LCL patient lesions were stained with anti-L. mexicana antibodies
for the parasite count. These 6 biopsies had previously been taken
for routine diagnostic purposes. Taken together, parasites were
counted in a total number of 17 LCL patients with lesions ranging
between 1 and 1.5 cm.
Results
Polymorphism analysis
Within the control group, all SNPs were found to be in Hardy
Weinberg equilibrium (HWE) with a p-value of p=0.0226 and for
cases (including LCL and DCL patients) they were in HWE with a
p-value of p=0.024. We also calculated the HWE with cases and
controls as one population with the Haplowiew 4.1 software where
the HWE test failed yielding a p-value of p=0.4998. The
comparison of the genotype frequencies between LCL patients
and controls for the IL-1b polymorphism showed that the
homozygote frequencies were higher in the controls for both of
the alleles, whereas the heterozygote frequency was higher in LCL
patients compared to controls (60.3% y 38.2%, respectively) see
TABLE 1. This suggests that we may have a risk associated to the
development of the disease for the heterozygous genotype as
opposed to a single allele risk association. As mentioned above, the
odd ratios resulting of comparing the heterozygote C/T to the
homozygote groups were found to be significant. The OR that
compared it to the homozygote C/C was 3.23 [p-value=0.0167,
95% CI=(1.2,8.7)]; the OR that had the homozygote T/T as
reference group was 2.19 [p-value=0.0274, 95% CI=(1.08,4.4)].
All other ORs calculated are shown in TABLE 2. In contrast, the
IL-1b in Patients Infected with L. mexicana
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significant (data not shown).
Since the sample size of DCL patients is only 6, it is
questionable to draw any conclusions from this sample. As an
exploratory step for further research, we repeated the procedure
above using all leishmaniasis patients (58 LCL and 6 DCL) as the
case group. Results for IL-1b were again statistically significant:
OR=3.7 when the heterozygote C/T is compared to the
homozygote C/C [p=0.006, 95% CI=(1.38,9.85)] and
OR=2.4 when the heterozygote C/T is compared to the
homozygote T/T [p=0.012, 95% CI=(1.19,4.6)]. There seems
to be no change in the conclusions drawn for the LCL patients.
However, this might be due entirely to the sample size of the DCL
group. No analysis was performed using only DCL patients as
cases, due to the small sample size. Based on the discussion of
Sasieni (1997) [24], we decided not to use the allelic OR. The
second-order analysis (gene-gene association) of the samples used
in this study showed no significant results (data not shown).
Serum IL-1b analysis by Western-blot
The analysis of IL-1b expression in sera of LCL and DCL
patients showed a different expression between both groups of
patients. LCL patients showed a lower expression of this cytokine
(Figure 1A, lanes 5–13) and DCL patients showed enhanced
expression of IL-1b (Figure 1A, lanes 14–20). In contrast to
patients with leishmaniasis, controls showed only minimal
amounts of IL-1b (Figure 1A, lanes 1–4). A statistically significant
difference was found (Figure 1B) when comparing IL-1b
expression in sera from LCL patients vs controls (p=0.01), DLC
patients vs controls (p=0.0052) and when comparing DCL
patients vs LCL patients (p=0.019).
Cytokine production by monocytes
The analysis of IL-1b production revealed that non-stimulated
monocytes from patients with cutaneous leishmaniasis had a
significant increase of their production of IL-1b when compared
with healthy controls (p=0.015) (Figure 2). The individual analysis
of the IL-1b production by monocytes from patients showed that
the degree of IL-1b production could be related to the severity of
the disease, since it was highest in patients with DCL (478 pg/mL
in the DCL patient with the more severe form and 423 pg/mL in
the patient with the less severe form), as compared to LCL patients
in whom the production of IL-1b was between 50 to 336 pg/mL.
Immunohistochemistry
The analysis of IL-1b in lesions of LCL and DCL patients
showed that the cytokine distribution varied between both groups
of patients: in LCL lesions, we observed two possible patterns of
IL-1b expression, according to parasite numbers in the lesions. In
one group (Figure 3A) the cytokine was localized on the cell
surface, showing an intense stain. This type of stain was found in
lesions of LCL patients that harbored few parasites (Figure 3B).
The second group of LCL patients showed a diffuse distribution
pattern of IL-1b staining (Figure 3C), which correlated with the
diffuse staining of abundant remnants of parasites (Figure 3D). It is
noteworthy that the first group of LCL patients only had one small
ulcer, less than 1 cm in diameter, whereas the second group of
LCL patients had 3 to 6 active lesions which varied between 1 and
2 cm in diameter. In contrast, all DCL patients showed a diffuse
distribution of IL-1b throughout the lesions (Figure 3E) all of
which were also heavily infected with intact Leishmania mexicana
parasites (Figure 3F).
These results show that the characteristics of the distribution of
IL-1b in the tissue varies according to parasite numbers: LCL
patients with few parasites in their lesions only show cell
membrane staining, whereas all DCL patients, with abundant
intact parasites in their lesions as well as some LCL patients with
abundant destroyed Leishmania parasites, show a diffuse pattern of
IL-1b staining.
The number of IL-1b positive cells in the tissues was different
for each patient (18 to 410 cells) and did not have any correlation
with the time of evolution of the disease nor with the numbers
parasites (data not shown). The number of parasites was
significantly different in the lesions of LCL and DCL patients
(p=0.0003) (Figure 4).
Discussion
The aim of the present study was to determine single nucleotide
polymorphisms of IL-1b (2511), CXCL8 (2251) and IL-1RA
(+2018) in patients with cutaneous leishmaniasis infected with
Leishmania mexicana. We evaluated two groups of persons (cases and
controls) that lived in the same endemic region. This study for the
first time demonstrated polymorphism in the gene IL-1b 2511 in
Mexican-mestizo patients from Tabasco, a state with high
prevalence of patients with cutaneous leishmaniasis. Our results
show that 90% of the individuals infected with Leishmania mexicana
Table 1. Distribution of genotypic and allelic frequencies for IL-1b 2511 (C/T) polymorphism in cases and controls.
Subjects IL-1b (2511 C/T) genotypes number (%) Allele frequencies in % Gender % (M/F
1) Age (years)
CC CT TT C T
Cases 6 (10.3) 35 (60.3) 17 (29.4) 40.5 59.5 M=29, F=26 11–64
Controls 26 (21.1) 47 (38.2) 50 (40.7) 40.2 59.8 M=35, F=66 7–88
1M=Male, F=Femele, (3 cases and 22 controls, gender unknown). All patients were diagnosed by Giemsa-stained smears of the lesions, Montenegro skin
hypersensitivity test and/or ELISA against Leishmania.
doi:10.1371/journal.pntd.0001533.t001
Table 2. Statistical analysis of IL-1b 2511 SNP.
Group Reference group OR CI x
2 p-value
CT CC 3.23 (1.2,8.7) 5.72 0.016
TT CC 1.47 (0.5,4.1) 0.53 0.465
CT+TT CC 2.32 (0.9,6.0) 3.15 0.075
CT TT 2.19 (1.08,4.4) 4.86 0.027
CC TT 0.68 (0.2,1.9) 0.53 0.465
CT+TT TT 1.65 (0.8,3.2) 2.17 0.140
doi:10.1371/journal.pntd.0001533.t002
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www.plosntds.org 4 May 2012 | Volume 6 | Issue 5 | e1533Figure 1. IL-1b expression in serum of patients with cutaneous leishmaniasis. (A) Western blot of mature IL-1b (17 kDa) in 4 controls (1–4),
9 LCL patients (5–13) and 7 DCL patients (14–20). (B) Graph of percentage intensity of IL-1b bands with statistically significant differences between
controls vs LCL patients, controls vs DCL patients and LCL vs DCL patients. (Identical symbols above different bars are statistically significant: p,0.05).
doi:10.1371/journal.pntd.0001533.g001
Figure 2. Analysis of IL-1b cytokine production by non-stimulated monocytes purified with anti-CD14 magnetic beads from PBMC
of control subjects and patients with cutaneous leishmaniasis after 18 hours in vitro culture. Mean values obtained from 7 healthy
control subjects and 5 patients with leishmaniasis. (Identical symbols above two different bars are statistically significant: p,0.05).
doi:10.1371/journal.pntd.0001533.g002
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www.plosntds.org 5 May 2012 | Volume 6 | Issue 5 | e1533Figure 3. Immunohistochemistry for IL-1b and Leishmania mexicana staining in lesions of patients with cutaneous leishmaniasis. (A)
IL-1b staining on cells of LCL patient with single small lesion; (B) small clusters of Leishmania parasites in LCL patient with small ulcer; (C) diffuse
distribution of IL-1b in LCL patient with abundant ulcers; (D) disintegrated Leishmania in LCL patient with abundant ulcers; (E) diffuse distribution of
IL-1b in Patients Infected with L. mexicana
www.plosntds.org 6 May 2012 | Volume 6 | Issue 5 | e1533had, either a heterozygote genotype (CT), or were homozygous for
the minor allele (TT). Of these, 60% had the heterozygous
genotype (CT), as compared to only 38% for the healthy controls.
These data suggest that the presence of this polymorphism in a
heterozygous genotype may favor disease development in patients
infected with Leishmania mexicana.
Disease susceptibility or resistance has been correlated to
genetic variations [25]. Specifically, polymorphism in the gene
for IL-1b (2511) has been associated with increased inflammation
[26]. This cytokine activates the vascular endothelium, enhancing
adhesion molecule expression, which, in combination with local
vasodilatation, slows blood flow, permitting the tethering of
neutrophils to the vessel wall. Locally released CXCL8 acts as
an activator and chemoattractant for neutrophils [27], which can
produce significant damage due to the release of pro-inflammatory
granules and enzymes [28]. Inflammation has been shown to be a
hallmark in cutaneous leishmaniasis and various polymorphisms,
related to increased or extended inflammation, have been
associated with the disease [29–31]. Neutrophils have been shown
to play an important role in leishmaniasis. They are decisive for
the early establishment of the disease following delivery of
parasites by the bite of the sand fly [6] and their enhanced
recruitment has been shown to contribute to disease susceptibility
[8]. The facilitating role of neutrophils has been associated with
their capacity to phagocytose the parasites and rapidly transport
them from the infection site, thus avoiding the toxic effects of
complement and the local immune responses [7]. The inflamma-
tory response aids Leishmania-infected phagocytic cells to enter
lymphatic vessels, favoring parasite distribution towards peripheral
tissues [32]. It is therefore tempting to speculate that augmented
IL-1b production possibly facilitates disease progression in patients
with DCL by enhancing the inflammatory response and thereby
aiding parasite dissemination. Thus we suggest that IL-1b (2511
C/T) genotype heightens the risk of developing the disease due to
the fact that this polymorphism is located in the promoter region
of the IL-1b gene, which has been related to enhanced cytokine
production and enhanced inflammatory disease. We propose that
patients with this genotype are likely to be associated with an
enhanced production of the pro-inflammatory cytokine IL-1b,
when the patient is infected with Leishmania mexicana. The
enhanced in vitro production of IL-1b by monocytes, and the
augmented expression of this cytokine in sera of patients heavily
infected with Leishmania mexicana, possibly strengthen the impor-
tance of IL-1b as a factor to develop the more severe form of the
disease, although we cannot rule out that the enhanced IL-1b
production is a consequence, rather than a cause, of the more
severe form of the disease. Our data are in accordance with the
literature [33] regarding the presence of the pro-inflammatory
cytokine IL-1b in severe tissue lesions. Additionally, disease
exacerbation has also been related to IL-1b in the BALB/c mouse
model [34]. Furthermore it has been reported that IL-1b
2/2
C57BL/6 mice, infected with Leishmania major, were resistant to
experimental cutaneous leishmaniasis [35].
The enhanced production of IL-1b by monocytes and serum of
patients with the more severe form of the disease led us to analyze
the cytokine in tissue lesions of patients with varying disease
severity. We found that the distribution of IL-1b varied in tissue
lesions in accordance with the numbers of parasites present in
those lesions. Thus, in heavily infected lesions of some of the
patients with LCL and in all of the DCL patients, the secreted IL-
1b was found diffusely distributed within the lesions, whereas in
LCL patients with a lower number of parasites, IL-1b was found to
be within the cells. To the best of our knowledge, this differential
distribution of IL-1b, according to varying degrees of inflamma-
IL-1b in DCL patient; (F) clusters with abundant intact Leishmania parasites in DCL patient. Red arrows show IL-1b
+ staining and black arrows show L.
mexicana staining. (G) Normal skin was used as negative control for IL-1b immunostaining. (H) Control staining with secondary antibody. All sections
were counterstained with haematoxylin. (A–H) scale bar=50 mm. Immunostaining in tissue sections was visualized at a magnification of 4006.W e
show a representative result of different types of lesions within each group: LCL patients with one small ulcer: (n=8 for IL-1b staining and n=17 for L.
mexicana staining) (A and B); LCL patients with various ulcers (n=3) (C and D); DCL patients (n=6) (E and F).
doi:10.1371/journal.pntd.0001533.g003
Figure 4. Statistical analysis of the number of parasites/mm
2 in lesions between LCL and DCL patients. Mean values were obtained
from 17 LCL patients and 6 DCL patients with leishmaniasis. (Identical symbols above two different bars are statistically significant: p,0.05).
doi:10.1371/journal.pntd.0001533.g004
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production can be induced by microbial products via TLR
ligands. Our group has previously shown that Leishmania mexicana
lypophosphoglycan (LPG) is a TLR2 ligand, leading to cell
activation [36]. It is thus feasible, that the enhanced presence of
the parasite relates to an increased IL-1b production. The
differential distribution could be related to the possible presence
of an alternative (noncaspase-1) mechanism of generating active
forms of IL-1b extracellularly in tissues. This alternative activating
pathway has been reported for a number of molecules including
serine protease-3 released by infiltrating neutrophils, as well as for
other proteases such as elastase, matrix metalloprotease 9 and
granzyme A released from cytotoxic T cells and mast cell chymase,
which can process the IL-1b precursor into an active cytokine
[37,38]. It is noteworthy that neutrophils secrete serine protease-3
together with extracellular traps, which have been shown to be
released when the cells are stimulated with Leishmania or LPG
[39,40]. The overall consequence of the diffusely distributed IL-1b
in tissue lesions that are heavily infected with Leishmania mexicana is
not clear, since in LCL patients IL-1b was associated with parasite
destruction, whereas in DCL patients the parasite was not
destroyed, despite the equal distribution of IL-1b. It is therefore
tempting to speculate that IL-1b is not directly involved in parasite
killing, but rather in aiding the mobility of phagocytosed Leishmania
to be transported outside of the lesions. In DCL patients with
impaired leishmanicidal capacities, IL-1b possibly aids parasite
distribution by enhancing the inflammatory response. Thus,
enhanced IL-1b production and distribution seems more critical
in patients that have underlying problems limiting their leishma-
nicidal capacity, such as in patients with DCL. These results open
a new perspective regarding the dynamics of IL-1b release in
tissues heavily infected with Leishmania mexicana.
In conclusion, our data show that leishmaniasis patients with IL-
1b polymorphism have a heightened risk to develop the disease.
Additionally we show that patients with a more severe form of the
disease show an enhanced IL-1b production. Yet it remains to be
established if the polymorphism relates directly with disease
severity in patients infected with Leishmania mexicana. We propose
that this might be the case, based on reports that the
polymorphism is located in the promoter region of the IL-1b
gene which has been shown to lead to enhanced IL-1b production
[26].
Our data help shed new light on the genes involved in the
disease outcome. Further studies aimed at analyzing allelic and
genotypic distributions in the Mexican population will help clarify
the differences we observed between cases and controls in
polymorphisms implicated in susceptibility to leishmaniasis in
our population. Only a few genes that determine susceptibility in
the complex relationship between the parasite and the host
immune response have been identified [41]. The analysis of IL-1b
and other proteins that participate in inflammation like caspase-1
and -5 or NALP3, in a larger group of patients, could possibly help
define to what extent polymorphisms and enhanced production of
IL-1b contribute to various clinical forms of leishmaniasis.
Accession links for numbers/ID numbers for genes and proteins
mentioned in the text:
IL-1b:
Protein: http://www.uniprot.org/uniprot/P01584
Gene: http://www.ncbi.nlm.nih.gov/protein/NP_000567.1
(CXCL8) IL-8:
Protein: http://www.uniprot.org/uniprot/P10145
Gene: http://www.ncbi.nlm.nih.gov/protein/AAH13615.1
IL-1RA:
Protein: http://www.uniprot.org/uniprot/P18510
Gene: http://www.ncbi.nlm.nih.gov/protein/CAA36262.1
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